August 17, 2017 – Cynvenio Biosystems, Inc. announces the launch of a new breast cancer monitoring study in partnership with Saint Luke’s Cancer Institute in Kansas City, Missouri. The study’s goal is to evaluate the potential for early detection of recurrent breast cancer using LiquidBiopsy and natural killer (NK) cell testing in patients at high-risk of relapse after neoadjuvant chemotherapy.
August 8, 2017 - Cynvenio launches its second generation PD-L1 expression test. The new blood test offers improved analytic performance over the company’s first generation PD-L1 test, enabling highly sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer cells recovered from a simple blood draw.
July 27, 2017 – Cynvenio announced that its LiquidBiopsy rare cell and cell-free isolation platform has been deployed at Severance Hospital of the Yonsei University Health System. Located in Gangnam-Gu, Seoul, Severance Hospital is one of the oldest and largest university hospitals in South Korea and has been treating patients continuously for 130 years.
Visit Cynvenio at booth #S11 on Saturday, July 29th to learn more about the latest in ClearID Liquid Biopsy testing.
June 14, 2017 – Cynvenio announces four new distribution agreements for Cynvenio’s ClearID line of blood tests in Israel, Greece, Argentina, and South Korea.
June 4, 2017 — Download Cynvenio's poster from ASCO 2017 presenting preliminary data from the first year of our 211-patient TNBC clinical research study in a poster titled, “Use of serial multi-template liquid biopsies in triple negative breast cancer monitoring.”
June 1, 2017 – Cynvenio's LiquidBiopsy rare cell and cell-free isolation platform will be featured at the 2017 ASCO Annual Meeting at booth #23123. Also at the conference, study data collected via the LiquidBiopsy platform and supporting the utility of longitudinal monitoring of breast cancer patients will be published.
May 30, 2017 – Cynvenio to present preliminary data to support the utility of longitudinal monitoring of triple negative breast cancer patients using Cynvenio’s ClearID liquid biopsy tests at the 2017 ASCO Annual Meeting, June 2-June 6, 2017 in Chicago, Illinois.
May 16, 2017 – Cynvenio announces the release of its ClearID Lung Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of 11 genes known to be altered in lung cancer, this new test is designed to quickly and accurately identify tumor-related genetic mutations that can be treated with targeted therapies.
April 28, 2017 – Cynvenio in partnership with TME Research announced the launch of a new neoadjuvant breast cancer monitoring (NEAT) study. The multi-center registry study will include at least 10 centers and over 150 patients to be monitored over two years with Cynvenio’s ClearID Breast Cancer blood test.
April 27, 2017 – Cynvenio will feature its ClearID Total Insight Breast Cancer monitoring program at The American Society of Breast Surgeons (ASBS) Annual Meeting 2017 (booth #114).
April 3, 2017 – Cynvenio announces the immediate availability of two new antibody-based capture kits consisting of EGFR (epidermal growth factor receptor) and PSMA (prostate specific membrane antigen).
March 31, 2017 - Cynvenio Biosystems today announced the further expansion of its payor network with the signing of a new agreement with Blue Cross Blue Shield of Illinois (BCBS IL) allowing its members access to Cynvenio's broad menu of liquid biopsy testing services for cancer.
March 9, 2017 – Cynvenio will showcase its ClearID Total Insight Monitoring service at the 34th Annual Miami Breast Cancer Conference, the Young Survival Coalition (YSC) Summit, and the 27th Annual Interdisciplinary Breast Center Conference.
March 9, 2017 – Cynvenio Biosystems, Inc., a leader in personalized medicine technology and cancer diagnostics, today announced the availability of ClearID® Total Insight™ Breast Cancer, a liquid biopsy monitoring service for patients in treatment and survivors in remission. This comprehensive assessment of a patient’s biological health is designed to measure immune health status and detect genetic mutations associated with cancer.
February 23, 2017 – Cynvenio and Color announces a partnership to offer the Color Test, a hereditary cancer panel that analyzes 30 genes including BRCA1 and BRCA2 with Cynvenio’s ClearID® Breast Cancer test, a specialized next-generation sequencing (NGS) panel that interrogates 27 genes for somatic mutations in breast cancer.
February 10, 2017 – Cynvenio Biosystems will feature its LiquidBiopsy rare cell isolation platform at Molecular Med Tri-Con 2017, February 19-24, 2017 in San Francisco.
January 26, 2017 - Cynvenio Biosystems, Inc. and Milenia Labs announced a distribution agreement for Cynvenio’s ClearID® Breast Cancer. The agreement will make ClearID Breast Cancer exclusively available to customers through Milenia Labs and its network of 12 diagnostic centers in Mexico.
January 9, 2017 - Cynvenio has released its updated ClearID® Breast Cancer blood test. The new ClearID test identifies circulating tumor cell burden and detects emergent genetic alterations associated with resistance to therapy, and has been optimized to monitor patients with advanced breast cancer during initiation of therapy and at regular intervals following treatment.
December 22, 2016 - An MLO special feature article written by Cynvenio Chief Medical Officer, Dr. Paul Song discussing liquid biopsy as a promising new approach to monitor TNBC patients post-treatment.